Capricor Therapeutics (CAPR) Common Equity: 2011-2025
Historic Common Equity for Capricor Therapeutics (CAPR) over the last 15 years, with Sep 2025 value amounting to $83.9 million.
- Capricor Therapeutics' Common Equity rose 22.86% to $83.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.9 million, marking a year-over-year increase of 22.86%. This contributed to the annual value of $145.5 million for FY2024, which is 543.60% up from last year.
- Per Capricor Therapeutics' latest filing, its Common Equity stood at $83.9 million for Q3 2025, which was down 20.11% from $105.0 million recorded in Q2 2025.
- Capricor Therapeutics' Common Equity's 5-year high stood at $145.5 million during Q4 2024, with a 5-year trough of -$1.8 million in Q3 2023.
- Over the past 3 years, Capricor Therapeutics' median Common Equity value was $22.6 million (recorded in 2023), while the average stood at $53.6 million.
- As far as peak fluctuations go, Capricor Therapeutics' Common Equity plummeted by 111.59% in 2023, and later spiked by 3,918.69% in 2024.
- Quarterly analysis of 5 years shows Capricor Therapeutics' Common Equity stood at $31.4 million in 2021, then slumped by 62.43% to $11.8 million in 2022, then surged by 91.76% to $22.6 million in 2023, then skyrocketed by 543.60% to $145.5 million in 2024, then rose by 22.86% to $83.9 million in 2025.
- Its Common Equity was $83.9 million in Q3 2025, compared to $105.0 million in Q2 2025 and $127.6 million in Q1 2025.